Ne pas négliger le risque de surtraitement : l'exemple des antiépileptiques
Buclin T , Rothuizen Le , Reichhart M , Biollaz J
Revue médicale suisse 2 ( 61) 976 -980
1
2006
[Dose-response curve and preliminary clinical study of a laxative, lactilol].
Buclin T , Biollaz J , Walder M , Schelling Jl
Schweizerische Medizinische Wochenschrift 118 ( 50) 1925 -1927
1
1988
Effects of perfusion of human atrial natriuretic factor in normal volunteers
Waeber G , Bidiville J , Porchet M , Nussberger J
Schweizerische Medizinische Wochenschrift 116 ( 49) 1733
1986
Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Buclin T , Nussberger J , Burnier M , Brunner Hr
Kidney International 55
9
1996
Treatment of hypertensive crisis with captopril
Turini Ga , Brunner Hr , Biollaz J , Waeber B
Schweizerische Medizinische Wochenschrift 113 ( 52) 2006
2
1983
Profiles and variations of ambulatory arterial pressure in treated and untreated hypertensive patients
Brunner Hr , Biollaz J , Jacot des Combes B , Waeber B
Schweizerische Medizinische Wochenschrift 113 ( 10) 371 -372
1983
Liver transplantation in Lausanne
Chioléro R , Gonvers Jj , Mosimann F , Biollaz J
Revue médicale de la Suisse romande 112 ( 2) 121 -125
1
1992
Posology of drugs in the obese patient
Biollaz J , Schelling Jl
Therapeutische Umschau. Revue thérapeutique 44 ( 8) 601
1987
[Multiple diseases: should we treat them all?].
Buclin T , Biollaz J
Revue médicale suisse 1 ( 14) 941 -947
2005
[Generic drug prescribing: pilot study on the impact of the new drug pricing system on costs and potential savings].
Wasserfallen Jb , Pannatier A , Biollaz J , Shimia S
Revue médicale suisse 2 ( 59) 865
1
2006
[The blood-brain barrier: recent insights].
Buclin T , Biollaz J
Revue médicale suisse 1 ( 14) 959 -963
2
2005
Comparison of propacetamol and morphine in postoperative analgesia
Vuilleumier Pa , Buclin T , Biollaz J
Schweizerische Medizinische Wochenschrift 128 ( 7) 259 -263
7
1998
[Factors aggravating the anemia in chronic hemodialysis: destruction or loss?].
Delaloye-Bischof A , Biollaz J , Wauters Jp , Delaloye B
Schweizerische Medizinische Wochenschrift 110 ( 49) 1888
1980
Clinical application of orally active angiotensin converting enzyme inhibitors
Gavras H , Gavras I , Brunner Hr , Biollaz J
Advances in Experimental Medicine and Biology 1127
1983
Clinical pharmacology of atrial natriuretic (3-28) eicosahexapeptide.
Nussberger J , Brunner Hr , Biollaz J , Waeber B
Journal of Hypertension 4 ( 2)
18
1986
Effect of synthetic atrial natriuretic factors on various regional blood flows in the healthy subject
Brunner Hr , Biollaz J , Waeber B , Jaggi C
Archives Des Maladies Du Coeur Et Des Vaisseaux 79 ( 6) 961 -966
1
1986
Clinical experiences with atrial natriuretic factor
Nussberger J , Biollaz J , Waeber B , Brunner Hr
Schweizerische Medizinische Wochenschrift 117 ( 49) 1937
1987
The treatment of cardiac insufficiency with vasodilators
Biollaz J , Munafo A
Schweizerische Medizinische Wochenschrift 118 ( 17) 616
1988
Troubles électrolytiques d'origine médicamenteuse: aspects physiologiques et physiopathologiques
J. Biollaz , F. Steinhauslin
Medecine Et Hygiene 47 ( 1791) 1202 -1213
1989
Administration entérale ou parentérale : entre croyances et abus : Thérapeutique
T. Buclin , E. Tamches , J. Biollaz
Medecine Et Hygiene 59 ( 2342) 833 -837
2001